Overview |
bs-1367R-APC |
VHL/HRCA1 Polyclonal Antibody, APC Conjugated |
FCM, IF(IHC-P), IF(IHC-F), IF(ICC) |
Human |
Mouse, Rat, Dog, Cow |
Specifications |
APC |
Rabbit |
KLH conjugated synthetic peptide derived from human VHL |
101-213/213 |
Polyclonal |
IgG |
1ug/ul |
Purified by Protein A. |
Aqueous buffered solution containing 0.01M TBS (pH7.4) with 1% BSA, 0.03% Proclin300 and 50% Glycerol. |
Store at -20°C. Aliquot into multiple vials to avoid repeated freeze-thaw cycles. |
Target |
7428 |
Cytoplasm, Nucleus, Cell membrane |
Von Hippel Lindau; von Hippel-Lindau syndrome protein homolog; Hippel-Lindau disease tumor suppressor VHL; von Hippel-Lindau tumor suppressor isoform 1; VHL; HRCA1; RCA1; VHL1; von Hippel-Lindau disease tumor suppressor isoform 2;pVHL; pVHL; G7 protein; Elongin binding protein; Protein G7; VHL 1; VHL_HUMAN;VHL1; VHLH; Von Hippel Lindau disease tumor suppressor; von Hippel Lindau syndrome; von Hippel Lindau tumor suppressor; Von Hippel-Lindau disease tumor suppressor. |
Von Hippel-Lindau syndrome (VHL) is a dominantly inherited familial cancer syndrome predisposing to a variety of malignant and benign tumors. A germline mutation of this gene is the basis of familial inheritance of VHL syndrome. The protein encoded by this gene is a component of the protein complex that includes elongin B, elongin C, and cullin-2, and possesses ubiquitin ligase E3 activity. This protein is involved in the ubiquitination and degradation of hypoxia-inducible-factor (HIF), which is a transcription factor that plays a central role in the regulation of gene expression by oxygen. RNA polymerase II subunit POLR2G/RPB7 is also reported to be a target of this protein. Alternatively spliced transcript variants encoding distinct isoforms have been observed. [provided by RefSeq]. |
Application Dilution |
FCM |
1:20-100 |
IF(IHC-P) |
1:50-200 |
IF(IHC-F) |
1:50-200 |
IF(ICC) |
1:50-200 |